Extranodal NK/T-Cell Lymphoma, Nasal Type · line 2 · Avelumab monotherapy for r/r NK/T-cell nasal lymphoma (off-label)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-AVELUMAB-MONO-NK-T |
| ID | IND-NK-T-NASAL-2L-AVELUMAB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-NK-T-NASAL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB. Major UA access barrier. Always plan as bridge to alloSCT in fit. PD-L1 IHC desirable for prognostic stratification but not required for treatment selection (response also seen in low-PD-L1).
Used By
Algorithms
ALGO-NK-T-NASAL-2L- ALGO-NK-T-NASAL-2L